In a significant development, Zydus Lifesciences Ltd has attained final approval from the US Food and Drug Administration (USFDA) for its generic version of Dapsone gel, primarily used in the treatment of acne. The regulatory nod covers the formulation in the strength of 7.5 percent, as disclosed by Zydus Lifesciences in a regulatory filing.

The approval marks a milestone for Zydus Lifesciences, affirming its commitment to providing effective and affordable healthcare solutions to patients. The Dapsone gel will be manufactured at the company’s topical manufacturing facility located in Changodar, Ahmedabad.

Dapsone gel is a widely used medication for addressing acne-related concerns, and Zydus Lifesciences’ entry into this segment is expected to offer patients access to a quality generic alternative. With this approval, the company further solidifies its presence in the global pharmaceutical market and reinforces its dedication to enhancing healthcare accessibility.